Side-by-side · Research reference

SemaglutidevsTesamorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified15/53 cited

BFDA-ApprovedVerified27/68 cited

Semaglutide

GLP-1 RA · FDA-Approved

0.25–2.4 mgWeekly doseWEGOVY (semaglutide) injection 2021

14.9%Body-weight ↓Wilding 2021

~7 daysHalf-lifeWEGOVY (semaglutide) injection 2021

SQ · Abdomen / thigh / arm · Once weekly

Tesamorelin

GHRH Analogue · FDA-Approved

2 mgDaily doseEGRIFTA® (tesamorelin for inje 2010

15–20%VAT reductionFalutz 2010

~26 minHalf-lifeEGRIFTA® (tesamorelin for inje 2010

SQ · Abdomen · Once Daily

01Mechanism of Action

Parameter

Semaglutide

Tesamorelin

Primary target

GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021

Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010

Pathway

GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021

GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007

Downstream effect

Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021

Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Yes — physiological pulsatility preserved

Origin

Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021

Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010

Antibody development

—

~50% after 26 wks (non-neutralising in most)Sévigny 2018

02Dosage Protocols

Parameter

Semaglutide

Tesamorelin

Standard dose (T2D, Ozempic)

0.5–1.0 mg / weekWEGOVY (semaglutide) injection 2021

—

Standard dose (weight, Wegovy)

2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021 Wilding 2021

—

Frequency

Once weekly, same day each week

Once daily (morning or pre-sleep)

Aligns with natural GH pulse.

Titration schedule

0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTsWilding 2021 WEGOVY (semaglutide) injection 2021

RCT / FDA-approvedFalutz 2007 Falutz 2010

Duration

Indefinite for chronic indication

Discontinuation results in weight regain.

12–52 weeks

VAT returns within months of stopping.

Reconstitution

Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.

Sterile water per labeling

Preserved at 2–8 °C after reconstitution.

Timing

Any time of day, with or without food

Empty stomach, pre-sleep preferred

Half-life

~7 days (168 h)WEGOVY (semaglutide) injection 2021

~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010

Modified vs native GHRH (7 min t½).

Standard dose

—

2 mg / dayEGRIFTA® (tesamorelin for inje 2010

FDA-approved protocol.

Lower / starter dose

—

1 mg / dayFalutz 2010

1 mg still produces significant IGF-1 elevation.

03Metabolic / Fat Loss Evidence

Parameter

Semaglutide

Tesamorelin

Primary fat target

—

Visceral adipose tissue (VAT) — abdominal

Quantified reduction

—

15–20% VAT ↓Falutz 2010

By CT at 26 weeks (Falutz et al., NEJM).

IGF-1 impact

—

+66 ng/mL (2 mg dose) · +81% mean elevationFalutz 2007

Effect on lean mass

—

Modest lean mass preservation / slight increase

Insulin sensitivity

—

Neutral to slight impairment (monitor HbA1c)Clarke 2018

Triglycerides

—

Significant TG reduction noted in Phase 3Falutz 2010

Glucose metabolism

—

Generally neutral; 4.5% HbA1c elevation riskClarke 2018

Effect reversibility

—

VAT returns within months of stopping

Key publication

—

Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007 Falutz 2010 EGRIFTA® (tesamorelin for inje 2010

04Side Effects & Safety

Parameter

Semaglutide

Tesamorelin

GI symptoms

Nausea, vomiting, diarrhea, constipation (very common)Wilding 2021

Nausea, diarrhea (mild, transient)

Injection site reaction

Mild erythema, pruritus

Erythema, pruritus, redness (common)

Pancreatitis risk

Rare; discontinue if suspectedWEGOVY (semaglutide) injection 2021

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021

—

Hypoglycemia

Low risk as monotherapy; elevated when combined with sulfonylureas / insulin

—

Gallbladder events

Increased cholelithiasis

—

Pregnancy / OB

ContraindicatedWEGOVY (semaglutide) injection 2021

ContraindicatedEGRIFTA® (tesamorelin for inje 2010

Heart rate

Modest ↑ resting HR (~2-4 bpm)

—

Fluid retention / Edema

—

Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)

Glucose intolerance

—

HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018

IGF-1 elevation

—

Dose-dependent; supraphysiological levels = discontinue

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010

Antibody formation

—

~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018

Absolute Contraindications

Semaglutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2
·Pregnancy / breastfeeding
·Hypersensitivity to semaglutide

Tesamorelin

·Active malignancy or history of treated cancer
·Pregnancy
·Hypersensitivity to tesamorelin or mannitol
·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)

Relative Contraindications

Semaglutide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy (may worsen with rapid glycemic improvement)

Tesamorelin

·Untreated diabetes (monitor HbA1c)
·Severe carpal tunnel syndrome
·Acute critical illness

05Administration Protocol

Parameter

Semaglutide

Tesamorelin

1. Reconstitution / device

Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.

Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.

Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.

3. Timing

Once weekly, same day. Day can be changed if ≥2 days separate doses.

Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.

4. Storage

Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.

5. Needle

Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.

27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.

06Stack Synergy

Semaglutide

+ Tirzepatide

Weak

View Tirzepatide →

Combining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.

Note: Stack not recommended — choose one GLP-1 RA
Primary benefit: (none — additive toxicity, no synergy)

Tesamorelin

+ Ipamorelin

Strong

View Ipamorelin →

Tesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.

Tesamorelin: 2 mg SQ · evening
Ipamorelin: 200–300 mcg SQ · same injection
Frequency: Once daily, pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep quality

Raun 1998